Now is the time to think. The increasing number of non-insured indications and the steadily increasing number of indications for new drugs have now become quite a big snowball. In an age when a single drug has multiple indications and is used for multiple diseases, the emergence of drugs that target specific gene mutations and further activate the immune system itself has made it possible to focus on the mechanism, not the disease, and apply its efficacy to a wide range. The domestic drug price system, which has a mechanism of decreasing as the amount of use, that is, increases, makes negotiations between the government and pharmaceutical companies lengthy, and patients wait longer. How should we accept the existence